Related Experiment Videos

The clinical effectiveness of Movicol in children with severe constipation: an outcome audit

Sandra Hanson1, Nav Bansal

  • 1Children's Resource Centre, Darent Valley Hospital, Kent.

Paediatric Nursing
|March 21, 2006
PubMed

Insights

Polyethylene glycol 3350 plus electrolytes (PEG+E) effectively managed severe pediatric constipation, reducing hospital admissions and home visits. This treatment, combined with a support service, proved clinically and economically beneficial for children.

Area of Science:

  • Pediatric Gastroenterology
  • Clinical Audit
  • Pharmacological Management

Background:

  • Severe pediatric constipation poses significant clinical and economic burdens.
  • Existing treatments may have limitations in effectiveness and patient adherence.
  • The role of polyethylene glycol 3350 plus electrolytes (PEG+E) in severe cases requires further evaluation.

Purpose of the Study:

  • To audit the clinical effectiveness of PEG+E (Movicol) for severe pediatric constipation.
  • To assess the impact of a community children's nursing team (CCNT) support service.
  • To evaluate parental satisfaction and resource utilization with PEG+E treatment.

Main Methods:

  • A seven-day disimpaction regimen followed by maintenance PEG+E dosing.
  • Parental questionnaires assessed previous and current treatment experiences.
  • Data collected on bowel movements, hospital admissions, home visits, and support service utilization.

Main Results:

  • Prior to PEG+E, 57% of children required hospital admission and 26% home visits for constipation.
  • Post-treatment, no children needed hospital admission or home visits.
  • 96% of parents reported high satisfaction with constipation control using PEG+E.

Conclusions:

  • PEG+E is clinically effective in managing severe pediatric constipation.
  • Integrating a CCNT support service enhances treatment outcomes and parental satisfaction.
  • PEG+E treatment, with support, offers both clinical and economic advantages.

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Drugs Affecting GI Tract Motility: Other Laxatives01:20

Drugs Affecting GI Tract Motility: Other Laxatives

Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents01:20

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Gastrointestinal Motility Disorders01:20

Gastrointestinal Motility Disorders

Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...